Interaction of multiple sclerosis serum with liposomes containing ganglioside GM1

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Annals of Neurology

• Publication date

  1980-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/ana.410070615PMID 7436364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What if multiple sclerosis isn't an immunological or a viral disease? the case for a circulating toxin

  1979cited by this paper
• The effect of heat inactivation of serum on aggregation of immunoglobulins.

  1979cited by this paper
• STALOSYLGALACTOSYL CERAMTDE AS A SPECIFIC MARKER FOR HUMAN MYELIN AND OLIGODENDROGLIAL PERIKARYA: GANGLIOSIDES OF HUMAN MYELIN, OLIGODENDROGLIA AND NEURONS

  1979cited by this paper
• Hemifacial spasm and the facial nucleus

  1978cited by this paper
• Multiple specificities of antibrain antibodies in multiple sclerosis and chronic myelopathy.

  1978cited by this paper
• Choleragen-mediated release of trapped glucose from liposomes containing ganglioside GM1.

  1976cited by this paper
• Serological reactions against glycolipid-sensitised liposomes in multiple sclerosis

  1976cited by this paper
• Deactivation of cholera toxin by a sialidase-resistant monosialosylganglioside.

  1973cited by this paper
• Interaction of Vibrio cholerae enterotoxin with cell membranes.

  1973cited by this paper
• Tissue Receptor for Cholera Exotoxin: Postulated Structure from Studies with GM1 Ganglioside and Related Glycolipids

  1973cited by this paper
• Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten.

  1969cited by this paper
• Sphingolipid Antibodies in Sera of Animals and Patients with Central Nervous System Lesions.∗

  1962cited by this paper
• [Progressive facial hemiatrophy].

  1956cited by this paper
• A MANUAL OF DISEASES OF THE NERVOUS SYSTEM

  1888cited by this paper
• Progressive facial hemiatrophy with some unusual symptoms

  year unknowncited by this paper

• Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis

  2024cites this paper
• Antikörper gegen die Ganglioside GM1, GD1b, GQ1b und das Myelin-assoziierte-Glykoprotein (MAG) im Serum von Patienten mit Multipler Sklerose

  2005cites this paper
• Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis.

  2003cites this paper
• Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis

  1998cites this paper
• Presence and isotype of anti-ganglioside antibodies in healthy persons, motor neuron disease, peripheral neuropathy, and other diseases of the nervous system

  1995cites this paper
• Identification and localization of the GM1 ganglioside in the cochlea using thin-layer chromatography and cholera toxin.

  1994cites this paper
• ELISA-type titertray assay of IgM anti-GM1 autoantibodies.

  1994cites this paper
• Polyclonal IgM anti‐GM1 ganglioside antibody in patients with motor neuron disease and variants

  1990cites this paper
• Monoclonal IgMs with anti-Gal(beta 1-3) GalNAc activity in lower motor neuron disease; identification of glycoprotein antigens in neural tissue and cross-reactivity with serum immunoglobulins.

  1989cites this paper
• Effect of antiglycolipid antisera on the lipid composition of cultured mouse spinal cords.

  1986cites this paper
• Anti-glycolipid antibodies and their immune complexes in multiple sclerosis.

  1986cites this paper
• Complement-dependent immune damage to liposomes containing gangliosides.

  1985cites this paper
• Abnormalities of serum and plasma components in patients with multiple sclerosis

  1985cites this paper
• Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE.

  1984cites this paper
• Biological approaches to the controlled delivery of drugs: a critical review.

  1984cites this paper
• Immune lysis of lipid vesicles containing myelin basic protein or glycolipid antigens by multiple sclerosis and normal sera.

  1984cites this paper
• Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE.

  1984cites this paper
• Antibodies to Glycosphingolipids in Patients with Multiple Sclerosis a

  1984cites this paper
• Immunological expression of gangliosides in multiple sclerosis and in a demyelinating model disease in rabbits.

  1984cites this paper
• A review of the immunogenic and immuno-modulatory properties of glycosphingolipids.

  1984cites this paper
• Studies of autoimmunity in multiple sclerosis.

  1984cites this paper
• Immune reactivity against membranes containing ganglioside GM1 in chronic-progressive multiple sclerosis: observation by spin-membrane immunoassay.

  1984cites this paper
• Elevated ganglioside concentration in serum and peripheral blood lymphocytes from multiple sclerosis patients in remission.

  1982cites this paper
• Preparation of anti-GM4 antiserum and its assay by a solid-phase radioimmunoassay.

  1982cites this paper
• Enzyme-linked immunosorbent assay (ELISA) for detection of antibodies against glycosphingolipids and its application to patients with systemic lupus erythematosus.

  1981cites this paper
• Multi-sialo brain gangliosides are powerful stimulators of active E-rosetting lymphocytes from multiple sclerosis patients.

  1981cites this paper
• Myelin basic protein interacts with the myelin-specific ganglioside GM4.

  1981cites this paper